Mereo Biopharma

Mereo Biopharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner. Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options. Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates. Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence. Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

Company Details

Employees
46
Founded
-
Address
1 Cavendish Place, London,w1g 0qf,united Kingdom
Phone
4403330237300
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
London
Looking for a particular Mereo Biopharma employee's phone or email?

Mereo Biopharma Questions

News

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights GlobeNewswire

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights - Yahoo Finance

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights Yahoo Finance

Mereo BioPharma Reports Q1 2025 Financial Results and Updates on Phase 3 Orbit Study of Setrusumab for Osteogenesis Imperfecta - Quiver Quantitative

Mereo BioPharma Reports Q1 2025 Financial Results and Updates on Phase 3 Orbit Study of Setrusumab for Osteogenesis Imperfecta Quiver Quantitative

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 - Yahoo Finance

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 Yahoo Finance

Mereo BioPharma Updates on Phase 3 Study of Setrusumab and Positive EMA Opinion for Alvelestat in Rare Diseases - Quiver Quantitative

Mereo BioPharma Updates on Phase 3 Study of Setrusumab and Positive EMA Opinion for Alvelestat in Rare Diseases Quiver Quantitative

Check out Mereo BioPharma Group PLC's stock price (MREO) in real time - CNBC

Check out Mereo BioPharma Group PLC's stock price (MREO) in real time CNBC

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market - Yahoo Finance

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market Yahoo Finance

Ultragenyx and Mereo BioPharma Progress Phase 3 Study of Setrusumab in Pediatric Osteogenesis Imperfecta Patients - Quiver Quantitative

Ultragenyx and Mereo BioPharma Progress Phase 3 Study of Setrusumab in Pediatric Osteogenesis Imperfecta Patients Quiver Quantitative

Mereo BioPharma Group plc (MREO): A Bull Case Theory - Yahoo Finance

Mereo BioPharma Group plc (MREO): A Bull Case Theory Yahoo Finance

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments - GlobeNewswire

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments GlobeNewswire

Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds? Yahoo Finance

Mereo BioPharma Announces Completion of $70 Million Private Placement - GlobeNewswire

Mereo BioPharma Announces Completion of $70 Million Private Placement GlobeNewswire

Mereo BioPharma Group plc ("Mereo" or the "Company" or the - GlobeNewswire

Mereo BioPharma Group plc ("Mereo" or the "Company" or the GlobeNewswire

MREO - Mereo Biopharma Latest Stock News & Market Updates - Stock Titan

MREO - Mereo Biopharma Latest Stock News & Market Updates Stock Titan

Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab - GlobeNewswire

Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab GlobeNewswire

Mereo BioPharma: Good Science, Fairly Valued (NASDAQ:MREO) - Seeking Alpha

Mereo BioPharma: Good Science, Fairly Valued (NASDAQ:MREO) Seeking Alpha

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI (MREO) - Seeking Alpha

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI (MREO) Seeking Alpha

Ultragenyx And Mereo's Setrusumab For Osteogenesis Imperfecta: Criticisms And Concerns - Seeking Alpha

Ultragenyx And Mereo's Setrusumab For Osteogenesis Imperfecta: Criticisms And Concerns Seeking Alpha

Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals - GlobeNewswire

Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals GlobeNewswire

Mereo BioPharma Group plc ("Mereo" or the "Company" or the - GlobeNewswire

Mereo BioPharma Group plc ("Mereo" or the "Company" or the GlobeNewswire

Top Mereo Biopharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant